[Treatment of disorders of lipid metabolism with the new lipid regulator X50].
With the newly developed lipid regulant X 50 = 1-benzyl-3-(1-carboxyl-methylethoxy)-4-methylpyrazol 15 patient with primary hypercholesterolaemia and hypertriglyceridaemia were treated for 3 months. A significant decrease of the serum triglycerides by 47% in all patients and of the total cholesterol by 32% in half the patients (LDL cholesterol decrease 25%) was the result. Altogether an increase of the linoleic acid of 14% and a decrease of the uric acid of 16% were furthermore the result. There were practically no side effects.